Cassava Sciences Inc Cash Flow Conversion Efficiency
Cassava Sciences Inc cash flow conversion efficiency. Based on the latest financial reports, Cassava Sciences Inc (SAVA) has a cash flow conversion efficiency ratio of -0.130x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.88 Million) by net assets ($68.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Cassava Sciences Inc (1999–2025)
Cash flow conversion efficiency of Cassava Sciences Inc from 1999 to 2025. This chart illustrates how Cassava Sciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View SAVA stock price for real-time trading data and today's change.
Cassava Sciences Inc Cash Flow Conversion Ratio Explained
Cassava Sciences Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Cassava Sciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cassava Sciences Inc ranked by their cash flow conversion efficiency. Also see market cap of Cassava Sciences Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ConvaTec Group PLC
LSE:CTEC
|
0.086x |
|
Maan Aluminium Limited
NSE:MAANALU
|
0.076x |
|
NFON AG
XETRA:NFN
|
0.024x |
|
Cinclus Pharma
ST:CINPHA
|
-0.425x |
|
Invesco High Income Trust II
NYSE:VLT
|
0.019x |
|
DrayTek Corp
TW:6216
|
0.002x |
|
Mandom Indonesia Tbk
JK:TCID
|
0.032x |
|
COWELL FASHION Co.Ltd
KQ:033290
|
0.004x |
Annual Cash Flow Conversion Efficiency for Cassava Sciences Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Cassava Sciences Inc from 1999 to 2025. Review SAVA cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $74.40 Million | $-32.25 Million | -0.433x | +45.98% |
| 2024-12-31 | $145.70 Million | $-116.93 Million | -0.803x | -34.49% |
| 2023-12-31 | $137.47 Million | $-82.03 Million | -0.597x | -75.15% |
| 2022-12-31 | $227.54 Million | $-77.51 Million | -0.341x | -186.46% |
| 2021-12-31 | $253.91 Million | $-30.20 Million | -0.119x | -103.73% |
| 2020-12-31 | $92.20 Million | $-5.38 Million | -0.058x | +48.69% |
| 2019-12-31 | $22.10 Million | $-2.51 Million | -0.114x | +53.19% |
| 2018-12-31 | $19.63 Million | $-4.77 Million | -0.243x | +71.38% |
| 2017-12-31 | $9.70 Million | $-8.24 Million | -0.849x | -29.37% |
| 2016-12-31 | $18.64 Million | $-12.23 Million | -0.656x | -112.94% |
| 2015-12-31 | $29.37 Million | $-9.05 Million | -0.308x | -29.31% |
| 2014-12-31 | $40.06 Million | $-9.55 Million | -0.238x | -65.75% |
| 2013-12-31 | $48.30 Million | $-6.95 Million | -0.144x | +73.65% |
| 2012-12-31 | $13.14 Million | $-7.17 Million | -0.546x | -9220.90% |
| 2011-12-31 | $44.39 Million | $-260.00K | -0.006x | -34.88% |
| 2010-12-31 | $32.93 Million | $-143.00K | -0.004x | +96.80% |
| 2009-12-31 | $108.25 Million | $-14.69 Million | -0.136x | -226.78% |
| 2008-12-31 | $104.29 Million | $11.16 Million | 0.107x | +398.57% |
| 2007-12-31 | $103.91 Million | $2.23 Million | 0.021x | +114.14% |
| 2006-12-31 | $77.92 Million | $-11.83 Million | -0.152x | -108.49% |
| 2005-12-31 | $63.36 Million | $113.23 Million | 1.787x | +612.48% |
| 2004-12-31 | $93.40 Million | $-32.57 Million | -0.349x | -30.19% |
| 2003-12-31 | $76.56 Million | $-20.51 Million | -0.268x | +13.20% |
| 2002-12-31 | $50.22 Million | $-15.50 Million | -0.309x | -63.67% |
| 2001-12-31 | $65.62 Million | $-12.37 Million | -0.189x | -100.90% |
| 2000-12-31 | $78.69 Million | $-7.39 Million | -0.094x | +68.16% |
| 1999-12-31 | $9.14 Million | $-2.69 Million | -0.295x | -- |
About Cassava Sciences Inc
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Cassav… Read more